Therapeutic Target Candidates
Drug should be safe, effective and tailored to the patient.
Drug safety & efficacy matter.
At Phenotype Pharmaceuticals, aside of our companion diagnostic business, we applied our know-how and proprietary technologies to focus on discovering tumor targets with distinct biological and clinical attributes that transcend the extensive heterogeneity of cancer signatures, and that we call them “Common Denominator Cancer Targets” (CDCT™). This CDCT™ includes the following characteristics:
• Phenotype Pharmaceuticals´ therapeutic target candidates are tumor markers expressed by cells that possess the attributes of tumor stem cells and are thus called tumor stem cell-like.
• They are expressed in the majority of patient population, not only in a limited fraction like most current therapeutic drug candidates.
• They are expressed across all disease stages.
• They either have a very limited expression in few normal organs or not expressed at all in the majority of major vital normal organs.
• Some of them are shown to be expressed only in fetal tissues.
At Phenotype Pharmaceuticals, we believe that these stringent criteria guide the best selection of therapeutics target candidates against tumors.
We successfully discovered several therapeutic candidates that possess the major attributes for therapeutic target candidates against major cancer and developed monoclonal antibodies to these candidates, all of which are in preclinical development stage.
PP-BH094, PP-MJC144, PP-BF618*, PP-BH077 and PP-BI59 are monoclonal antibodies to novel therapeutic target candidates with a demonstrated direct cancer cell killing properties and efficacy in vitro and in xenograft animal models. These product candidates are currently under pre-clinical development and will be developed initially for the treatment of colorectal, breast, pancreas, lung, prostate cancer and lymphoma. Based on their tumor expression profile, they also possess the potential for additional indications.
Targets recognized by these monoclonal antibodies were shown to be expressed in the majority of clinical samples of the disease population and are not expressed in the majority of vital organs such as liver, brain, heart.